Gao Huanjia, Liu Shiyu, Cai Hairong, Chen Dongjie, Fu Xue, Zhao Shuai, Chen Bojun
The Second Clinical Medical School, Guangzhou University of Chinese Medicine.
Department of Emergency, the Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine.
Medicine (Baltimore). 2020 Aug 7;99(32):e21589. doi: 10.1097/MD.0000000000021589.
Coronary heart disease (CHD) is the leading cause of morbidity and mortality worldwide. Guipi Decoction (GPD) is a classical traditional Chinese medication used to treat CHD. However, systematic review and meta-analysis regarding its efficacy and safety has not been systematically evaluated. The objective of this protocol is to determine the efficacy and safety of GPD in the treatment of CHD.
Randomized controlled trials evaluating the effectiveness and safety of GPD in the treatment of CHD will be retrieved from 8 electronic databases, including PubMed, EMBASE, Cochrane Library, Web of science, China National Knowledge Infrastructure Database, VIP Database, Wanfang Database and China Biology Medicine Database. Study selection, data collection, risk of bias assessment, and evaluation of the quality of evidence will be performed in order. Data will be analyzed by RevMan V.5.3.5 software.
This study will evaluate the efficacy and safety of GPD in the treatment of CHD.
This systematic review will provide evidence for determining whether or not GPD is an effective and safe intervention for CHD.
PROSPERO CRD 42020156420.
冠心病（CHD）是全球发病和死亡的主要原因。归脾汤（GPD）是用于治疗冠心病的经典中药方剂。然而，关于其疗效和安全性的系统评价和荟萃分析尚未得到系统评估。本方案的目的是确定归脾汤治疗冠心病的疗效和安全性。
将从8个电子数据库检索评估归脾汤治疗冠心病有效性和安全性的随机对照试验，这些数据库包括PubMed、EMBASE、Cochrane图书馆、科学网、中国知网数据库、维普数据库、万方数据库和中国生物医学数据库。将依次进行研究选择、数据收集、偏倚风险评估和证据质量评估。数据将使用RevMan V.5.3.5软件进行分析。
本研究将评估归脾汤治疗冠心病的疗效和安全性。
本系统评价将为确定归脾汤是否为治疗冠心病的有效和安全干预措施提供证据。
PROSPERO CRD 42020156420。
